Scientific publications

Innovative Strategies in Heart Failure: Present and Future

Rodríguez-Mañero M (1), Grigorian-Shamagian L (2), Rábago G (3), Abou-Jokh C (4), Álvarez B (1), Brion M (5), González-Juanatey JR (6)

(1) Departamento de Cardiología, Hospital Universitario Santiago de Compostela, Santiago de Compostela, España; Instituto para el Desarrollo e Integración de la Salud, Santiago de Compostela, España; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares, Madrid, España.
(2) Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares, Madrid, España; Hospital General Universitario Gregorio Marañón, Madrid, España.
(3) Clínica Universidad de Navarra, Pamplona, España.
(4) Departamento de Cardiología, Hospital Universitario Santiago de Compostela, Santiago de Compostela, España.
(5) Departamento de Cardiología, Hospital Universitario Santiago de Compostela, Santiago de Compostela, España; Instituto para el Desarrollo e Integración de la Salud, Santiago de Compostela, España.
(6) Departamento de Cardiología, Hospital Universitario Santiago de Compostela, Santiago de Compostela, España; Instituto para el Desarrollo e Integración de la Salud, Santiago de Compostela, España; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares, Madrid, España.

Magazine: Archives of Medical Research

Date: Dec 31, 2018

Cardiac Surgery [SP]

ABTRACT

Heart failure (HF) is a progressively debilitating disease that considerably decreases the life expectancy and quality of life.

It has become an important area of focus since it remains one of the most common reasons for admission in patients over the age of 65. Importantly, the incidence of HF has not declined within the past 20 years, but the survival after onset has increased in younger patients and men.

This has been in part due to the growing interest in therapies that may decrease morbidity, mortality, along with the substantial health care expenditures associated with the disease. It can be said that over the past 50 years, there have been three distinct eras relating to HF management; a) the non-pharmacologic era, focused its treatments on fluid restriction; b) the pharmacologic era, marked by the increased use of inotropes and diuretics and the discovery of vasodilators, and the posterior discovery of medications relating to neurohormonal pathways; c) the device era, with the discovery, acceptance, and increased use of implantable cardioverter defibrillators, cardiac resynchronization therapy (CRT), and left ventricular assist devices (LVADs) among others. A new forth era could be about to arrive, with the advent of regenerative therapies. In this review article will discuss new therapeutic discoveries as well as provide insight into future therapies.

CITATION  Arch Med Res. 2018 Dec 31. pii: S0188-4409(18)30914-7. doi: 10.1016/j.arcmed.2018.12.011

you maybe interested

WHAT TECHNOLOGY
DO WE USE?

The Clínica is the greater private hospital with technological equipment of Spain, all in a single center.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

OUR
PROFESSIONALS

The professionals of the Clínica perform continuous research and training, always to the benefit of the patient.

Imagen profesionales de la Clínica Universidad de Navarra

WHY CHOOSE
THE CLINICA?

Learn why we are different from other healthcare centers. Quality, speed, comfort and results.

Imagen del edificio de la Clínica Universidad de Navarra